Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36 | $31 | $35 | $40 |
| % Growth | 14.5% | -10.4% | -13.5% | – |
| Cost of Goods Sold | $10 | $9 | $14 | $11 |
| Gross Profit | $25 | $22 | $21 | $29 |
| % Margin | 70.6% | 70.6% | 59.8% | 72.5% |
| R&D Expenses | $7 | $16 | $15 | $16 |
| G&A Expenses | $0 | $38 | $2 | $38 |
| SG&A Expenses | $0 | $38 | $3 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $35 | $0 | $34 | -$3 |
| Operating Expenses | $42 | $54 | $52 | $52 |
| Operating Income | -$17 | -$32 | -$32 | -$23 |
| % Margin | -47.2% | -102.8% | -90.9% | -56.7% |
| Other Income/Exp. Net | -$6 | $2 | -$2 | -$3 |
| Pre-Tax Income | -$22 | -$30 | -$34 | -$25 |
| Tax Expense | -$2 | -$1 | -$1 | -$1 |
| Net Income | -$21 | -$29 | -$33 | -$25 |
| % Margin | -58.2% | -94.1% | -94.6% | -61.2% |
| EPS | -0.38 | -0.65 | -0.75 | -0.57 |
| % Growth | 41.5% | 13.3% | -31.6% | – |
| EPS Diluted | -0.38 | -0.65 | -0.75 | -0.57 |
| Weighted Avg Shares Out | 54 | 45 | 44 | 43 |
| Weighted Avg Shares Out Dil | 54 | 45 | 44 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$15 | -$28 | -$30 | -$22 |
| % Margin | -42.7% | -89.7% | -86.5% | -53.9% |